BE568046A - - Google Patents
Info
- Publication number
- BE568046A BE568046A BE568046DA BE568046A BE 568046 A BE568046 A BE 568046A BE 568046D A BE568046D A BE 568046DA BE 568046 A BE568046 A BE 568046A
- Authority
- BE
- Belgium
- Prior art keywords
- composition
- sep
- micrograms
- ethanolamine
- pharmaceutical carrier
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 35
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 230000004968 inflammatory condition Effects 0.000 claims description 18
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 200000000018 inflammatory disease Diseases 0.000 claims description 12
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- 229920002261 Corn starch Polymers 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- 239000008120 corn starch Substances 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 6
- 229960003178 Choline Chloride Drugs 0.000 claims description 6
- SGMZJAMFUVOLNK-UHFFFAOYSA-M Choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 6
- 235000019743 Choline chloride Nutrition 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- BOWVQLFMWHZBEF-KTKRTIGZSA-N Oleoylethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 229940076156 Streptococcus pyogenes Drugs 0.000 claims description 3
- NCPLWPQEVIBZKJ-UHFFFAOYSA-N 2-hydroxy-N-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC=C1O NCPLWPQEVIBZKJ-UHFFFAOYSA-N 0.000 claims description 2
- QZXSMBBFBXPQHI-UHFFFAOYSA-N N-(dodecanoyl)ethanolamine Chemical compound CCCCCCCCCCCC(=O)NCCO QZXSMBBFBXPQHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 14
- BXVMCDFADGTPHQ-UHFFFAOYSA-N 2-(2-hydroxyethyl)hexadecanamide Chemical compound CCCCCCCCCCCCCCC(C(N)=O)CCO BXVMCDFADGTPHQ-UHFFFAOYSA-N 0.000 claims 1
- SOLCGTLCIBOSQW-UHFFFAOYSA-N 2-acetyloxyethylazanium;chloride Chemical compound Cl.CC(=O)OCCN SOLCGTLCIBOSQW-UHFFFAOYSA-N 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 124
- 229940031098 ethanolamine Drugs 0.000 description 23
- 150000002169 ethanolamines Chemical class 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 210000003414 Extremities Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 201000003068 rheumatic fever Diseases 0.000 description 6
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 5
- 229940073579 ETHANOLAMINE HYDROCHLORIDE Drugs 0.000 description 5
- 230000002522 swelling Effects 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical class CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 208000003455 Anaphylaxis Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 230000003110 anti-inflammatory Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- -1 elixirs Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- HSEMFIZWXHQJAE-UHFFFAOYSA-N hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000002969 Egg Yolk Anatomy 0.000 description 2
- 210000001503 Joints Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 101710024753 SERPINB14 Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002949 hemolytic Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000001235 sensitizing Effects 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-O 2-(dimethylamino)ethyloxidanium Chemical compound C[NH+](C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-O 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- XENVCRGQTABGKY-ZHACJKMWSA-N Chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 206010044334 Trance Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE568046A true BE568046A (pt) |
Family
ID=187538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE568046D BE568046A (pt) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE568046A (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987004048A1 (en) * | 1986-01-13 | 1987-07-16 | A. Nattermann & Cie Gmbh | Use of membrane modulators and products comprising such membrane modulators |
-
0
- BE BE568046D patent/BE568046A/fr unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987004048A1 (en) * | 1986-01-13 | 1987-07-16 | A. Nattermann & Cie Gmbh | Use of membrane modulators and products comprising such membrane modulators |
| EP0231765A1 (en) * | 1986-01-13 | 1987-08-12 | A. Nattermann & Cie. GmbH | Use of membrane modulators and products comprising such membrane modulators |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI235060B (en) | Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia | |
| EP0001727B1 (fr) | Nouveaux dérivés du phényl-4-(trichloro-2',2',2'-éthoxycarboxamido)-2-thiazole utiles comme médicaments, compositions pharmaceutiques les contenant et leur procédé de préparation | |
| EP1067927B1 (en) | Antioxidant stabilizer system for pharmaceutical formulations | |
| CA2680433C (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| BE1015217A5 (pt) | ||
| HU218906B (hu) | Kristályos, nem mikroszkópos L-dopa-etilészter, ezt tartalmazó gyógyászati készítmények és eljárás előállításukra | |
| FR2490493A1 (fr) | Composition pharmaceutique ou alimentaire contenant de l'a -cetoglutarate de pyridoxine, procede pour sa preparation | |
| JP2023512622A (ja) | ニタゾキサニド及びその活性型であるチゾキサニドのＳＡＲＳ－ＣｏＶ－２感染症の治療への適用 | |
| EP0437128B1 (fr) | Utilisation des dérivés des fluoroquinolones pour le traitement de la pneumonie à Pneumocystis carinii | |
| BR122013012291B1 (pt) | uso de 3-o-acetil-4"-o-isovaleril-tilosina ou um sal de adição de ácido farmacologicamente aceitável ou outro derivado da mesma, ração para suínos, composição revestida estável para adição a uma ração animal e medicamento veterinário | |
| JPH0517352A (ja) | シユクラーゼ活性阻害剤 | |
| US4186206A (en) | Treatment of swine dysentery | |
| BE568046A (pt) | ||
| CA2312021C (fr) | Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose | |
| US3179562A (en) | Treatment of diabetes with alpha, alpha substituted acetic acid derivatives | |
| JPS6081127A (ja) | 食欲抑制剤 | |
| US3330724A (en) | Nitrofuran derivatives for treating coccidiosis | |
| US4205081A (en) | Composition and method for preventing or treating swine dysentery | |
| CA2056906C (en) | Use of phenylethanolaminotetralins for the preparation of anti-depressant and anti-stress pharmaceutical compositions | |
| WO1996011681A1 (fr) | Antidiarrheique therapeutique et preventif | |
| BE487577A (pt) | ||
| EP1901735B1 (fr) | Composes de type polyphenols pour la préparation de compositions destinées à prevenir ou traiter des maladies impliquant une proliferation cellulaire anormale | |
| CA1227136A (fr) | Compositions pharmaceutiques contenant a titre de principe actif l'acide 4-(benzofuran-2-yl)4-oxo buten-2-oique et/ou de ses sels pharmaceutiquement acceptables | |
| JPH0570604B2 (pt) | ||
| BE607336A (pt) |